Acute Effects of a Botanical Extract and Its Main Volatile Compound on Stress Response in Healthy Adults

Sponsor
Activ'inside (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04523870
Collaborator
CIC SANPSY (USR CNRS 3413), Groupe Hospitalier Pellegrin, Bordeaux, France (Other)
20
Enrollment
1
Location
3
Arms
15.4
Anticipated Duration (Months)
1.3
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The prevalence of stress in daily human life increase in the investigator's modern life style. Short stress, could be benefit for memory, but prolonged stress may conduct to disturbance in cardiovascular, neuroendocrine and central nervous systems. Moreover, it is well established that stress is the most common risk factor for the development of mood and anxiety disorders, such as major depressive disorder (MDD) and generalized anxiety disorder. In response to stress, hypothalamic-pituitary-adrenocortical (HPA) axis is one of activated pathway, which induce the cortisol release. Certain natural products could increase resilience to stress. Indeed, several preclinical studies have already showed that botanical extracts inhibited the typical plasmatic corticosterone elevation induced by an acute stress challenge. Therefore, the aim of this clinical trial is to investigate the acute effects of a botanical extract and one of his major compound, both delivered as sublingual single dose, on cortisol level, cardiac parameters, and psychometric response, in healthy adults exposed to an acute psychological stress.

Condition or DiseaseIntervention/TreatmentPhase
  • Dietary Supplement: Botanical extract
  • Dietary Supplement: Main compound of the botanical extract
  • Dietary Supplement: Placebo
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
20 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Other
Official Title:
Acute Effects of a Botanical Extract and Its Main Volatile Compound on Stress Response in Healthy Adults: Randomized, Cross-over (Three Arms), Double-blind, Placebo-controlled Clinical Trial
Actual Study Start Date :
Sep 16, 2020
Anticipated Primary Completion Date :
Dec 30, 2021
Anticipated Study Completion Date :
Dec 30, 2021

Arms and Interventions

ArmIntervention/Treatment
Experimental: Botanical extract

Dietary Supplement: Botanical extract
One capsule

Experimental: Major compound of the extract

Dietary Supplement: Main compound of the botanical extract
one capsule

Placebo Comparator: Placebo

Dietary Supplement: Placebo
Maltodextrin, one capsule

Outcome Measures

Primary Outcome Measures

  1. Cortisol response to an acute stress [Between baseline (before exposure to the stressor) and time 60 minutes after exposure to the stressor]

    Area under the curve of the salivary cortisol concentration

Secondary Outcome Measures

  1. Maximum salivary cortisol concentration [Between baseline (before exposure to the stressor) and time 60 minutes after exposure to the stressor]

  2. Time of maximum of salivary cortisol concentration [Between baseline (before exposure to the stressor) and time 60 minutes after exposure to the stressor]

  3. Maximum change in heart rate variability parameters [Between baseline (before exposure to the stressor) and time 60 minutes after exposure to the stressor]

  4. Area under the curve of heart rate variability parameters [Between baseline (before exposure to the stressor) and time 60 minutes after exposure to the stressor]

  5. Maximum increase in the anxiety score [Between baseline (before exposure to the stressor) and time 60 minutes after exposure to the stressor]

  6. Time of maximum increase in the anxiety score [Between baseline (before exposure to the stressor) and time 60 minutes after exposure to the stressor]

  7. Area under the curve of the anxiety score [Between baseline (before exposure to the stressor) and time 60 minutes after exposure to the stressor]

  8. Maximum increase in the perceived stress score [Between baseline (before exposure to the stressor) and time 60 minutes after exposure to the stressor]

  9. Time of maximum increase in the perceived stress score [Between baseline (before exposure to the stressor) and time 60 minutes after exposure to the stressor]

  10. Area under the curve of the perceived stress score [Between baseline (before exposure to the stressor) and time 60 minutes after exposure to the stressor]

  11. Percentage of correct answers in serial subtractions [During the subtractions tasks]

  12. Percentage of correct answers given during stress test [During the 60 minutes of the stress test]

  13. Mean number of total answers given per second. [During the 60 minutes of the stress test]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 25 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Non-smoker since at least 3 months

  • Body Mass Index (BMI) in the normal range: 18.5 ≤ BMI < 25 kg/ m2 or "normal corpulence" according to investigator's judgment

  • Usual waking hour between 6.00 and 9.00 am on weekdays

  • Displaying a pattern of "reactive responder" to the stressor

  • Subjects affiliated with a social security scheme

  • Subjects capable of and willing to comply with the protocol and to give their written informed consent

Exclusion Criteria:
  • Currently suffering from mental disorder or with personal history of such disease (depression, generalized anxiety disorder, obsessive compulsive disorder, panic disorder, simple phobia and social phobia, schizophrenia, …) according to the volunteer's self-declaration.

  • Anxiolytic, antidepressant or any other treatment likely to affect some of the study parameters, whatever the reason of its prescription within the previous 3 months.

  • Event (personal or professional) likely to have impacted the study parameters within 2 weeks before V1 (for example but not restricted to: change of professional function/ situation, death of a family member, divorce, surgery, accident, travel with jet lag …).

  • Event (personal or professional) likely to affect the study parameters planned within the next 11 weeks, including but not restricted to: vaccination, travel with jet lag, …

  • Systolic blood pressure > 140 mmHg or diastolic blood pressure > 90 mmHg during the V0 visit (Blood pressure will be measured while the subject sit in a chair. Blood pressure will be measured after a 10-minute rest and will be repeated 3 times separated by 3-minute intervals. The average of the 3 measurements will be calculated.)

  • Subjects diagnosed with at least one of the following will not be eligible:

  • Present or recurrent infectious diseases (including cystitis, gingivitis, conjunctivitis, respiratory infections, …)

  • Diabetes (type I or type II)

  • Cardiovascular or vascular disease or history of cardiovascular or vascular disease (such as thrombosis, phlebitis, CVA, heart disease)

  • Chronic disease affecting blood flow (examples: Raynaud's disease or syndrome, chronic veinous insuficiency)

  • Allergic disease (asthma, allergic rhinitis, atopic dermatitis, …) or chronic inflammatory pathology (tendinitis, Crohn's disease, coeliac disease, …)

  • Any other pathology which, according to investigator's judgment, is likely to affect the study parameters.

  • Usual corticoïd treatment/ steroidal anti-inflammatory treatment (ex: Bétaméthasone, Cortivazol, Dexamethasone, Methylprednisolone, Prednisolone, Prednisone, Tétracosactide, Triamcinolone, …) including local treatments (ex : Locoïd lotion, Locatop, Locapred, Tridesonit, etc). Subjects will not be eligible if they have consumed such treatments within 2 weeks before V1 and/ or if they are likely to consume such treatments during the study;

  • Oral antibiotic treatment within the last 2 weeks before entry into the study. In case of oral antibiotic started after inclusion, the next study visits of the participant will be reported until at least 2 weeks after the end of the antibiotic treatment.

  • Unbalanced thyroid disease. However, subjects with controlled thyroid diseases (medication unchanged within the last 3 months) can be included;

  • Suffering from a severe chronic pathology which, according to Investigator's judgment, is likely to affect at least one of the study parameters (such as but not restricted to: severe chronic pain, cancer or history of cancer unless in remission for more than 5 years, HIV, hepatitis, renal disease, cardiac disease);

  • High physical activity practice: more than 10 hours per week of moderate to vigorous physical activity, or physical activity practice modified since less than 2 months or likely to be significantly modified within the next 11 weeks. Examples of moderate physical activity are: transporting light loads, bicycling at a normal pace, a double tennis, ... Walking is not considered as physical activity of moderate intensity.

  • Subjects working in shift schedules (ex : nurse, baker, etc)

  • Subjects whose working conditions are variable and likely to be extreme (ex: work in a cold room);

  • Subjects consuming more than 3 coffee servings from waking until lunch (included), i.e. more than a bowl at breakfast + a cup in the morning + a cup at lunch.

  • Subjects consuming any food supplement (including vitamins, minerals and botanicals and/or other substances) and refusing to stop for at least 2 weeks before V1 (inclusion visit) and until the end of his study participation;

  • Usual alcohol consumption > 3 glasses/ day or chronic alcohol abuse treated since less than 3 months;

  • Subjects with usual consumption of recreational drug. Subjects with occasional consumption of recreational drug can be include if they agree not to consume such products for at least one week before V1 and until the end of their study participation.

  • Change in dietary habits since less than 4 weeks or planned within the next 11 weeks.

  • Eating disorders: anorexia and bulimia or unstable dietary pattern.

  • Any food allergy documented or suspected to one of the components of the study products.

  • Subject presenting a psychological or linguistic inability to sign the informed consent.

  • Subject under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision.

  • Subject having received indemnities for clinical trial reaching at least 4500 Euros considering the last 12 months.

  • Subject participating in another biomedical study or during the exclusion period of a previous study.

Contacts and Locations

Locations

SiteCityStateCountryPostal Code
1SANPSY (CHU Pellegrin)BordeauxFrance33076

Sponsors and Collaborators

  • Activ'inside
  • CIC SANPSY (USR CNRS 3413), Groupe Hospitalier Pellegrin, Bordeaux, France

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Activ'inside
ClinicalTrials.gov Identifier:
NCT04523870
Other Study ID Numbers:
  • SAFRAI2018
First Posted:
Aug 24, 2020
Last Update Posted:
Oct 7, 2021
Last Verified:
Oct 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Oct 7, 2021